Lexicon Pharmaceuticals, Inc. (LXRX Quick QuoteLXRX - Free Report) was a big mover last session, as its shares rose almost 17% on the day. The move came after the company released the results in its Phase 3 clincial trial of its sotagliflozin treatment for type 1 diabetes patients. This led to far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $13.88 to $16.24 in the past one-month time frame.

Over the last 30 days, the company witnessed one positive estimate revision while the Zacks Consensus Estimate moved higher, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday’s jump can turn into more strength down the road.

Lexicon Pharmaceuticals currently carries a Zacks Rank #3 (Hold) while its Earnings ESP is positive.

LEXICON PHARMA Price

 

LEXICON PHARMA Price | LEXICON PHARMA Quote

A better-ranked stock in the med-biomed/gene space is Geron Corporation (GERN Quick QuoteGERN - Free Report) , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is LXRX going up? Or down? Predict to see what others think: Up or Down

Confidential from Zacks

Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>